PPT Slide
Oral: Xatral OD (Sanofi Synthelabo)
- Indicated for treatment of benign prostatic hypertrophy
- Xatral multiple dose European sales of $100 million +
- Xatral OD: fastest conversion of multi-dose to single dose formulation in U.K. market
- “Approvable letter” received from FDA - October 2001
- US launch anticipated 2002
- Estimated global sales: $400 million